PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

The ethics of knowing where to stop treatment in a sick and elderly patient

2014-06-01
(Press-News.org) An Emeritus Professor of medical ethics at Imperial College London will deliver a presentation at this year's Euroanaesthesia meeting titled 'Escalating care for the comorbid elderly-where do we stop?". Raanan Gillon, who is President of the UK's Institute of Medical Ethics, will argue that a patient's age should not in itself be considered an ethically relevant criterion for deciding 'where to stop'.

Acknowledging that there is a morally plausible counter-argument – known in the UK as 'the fair innings argument'- according to which scarce life prolonging resources should be preferentially deployed to younger patients, Professor Gillon will argue against it. He says: "If societies do wish to pursue such 'ageist' policies then they should do so only do so after widespread consultation and the enactment of democratically established laws according to which patients condemned to be denied life-prolonging therapies on grounds of age alone should have a legal right of appeal!"

The moral criteria that are relevant can be summarised, he argues, as the likelihood of achieving a beneficial outcome for the patient, at the cost of a minimised and acceptable risk of harm, in the light of the patient's own views and values where these are ascertainable, and also in the context of fair consideration of competing claims on available resources.

"However, co-morbidity and age may in some circumstances justifiably have a bearing on these criteria," concludes Professor Gillon. "For example co-morbidity may adversely and substantially influence the probability of a beneficial outcome; and some old people may be less inclined than when they were younger to accept the risks and discomforts of major surgery even if it might prolong their lives."

INFORMATION: END


ELSE PRESS RELEASES FROM THIS DATE:

Study of 55 million people adds further evidence that patients admitted to hospital at weekends have higher mortality

2014-06-01
A systematic review and meta-analysis of hospital data worldwide, presented as this year's Euroanaesthesia meeting in Stockholm, adds further evidence that patients admitted to hospital at weekends have higher mortality than those admitted on weekdays. The study is by Dr Hiroshi Hoshijima, Tohoku University, Sendai, Japan, and colleagues. The analysis included 72 studies from various world regions, covering 55,053,719 participants. The authors found that weekend admission was associated with increased morality of between 15% and 17% depending on the statistical technique ...

Risk of death highest following surgery in afternoons, at weekends, and in February

2014-06-01
New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest. The research is by Dr Felix Kork and Professor Claudia Spies, Charité - University Medicine Berlin, Germany and colleagues. Hospital mortality is subject to day-night, weekly and seasonal variability. This has been shown for various populations, settings, and in different regions of the world. However, a cyclic influence on hospital mortality has not been shown in patients after surgery. ...

Poor coverage of specific gene sets in exome sequencing gives cause for concern

2014-06-01
With services based on exome sequencing becoming affordable to patients at a reasonable price, the question of the quality of the results provided has become increasingly important. The exome is the DNA sequence of genes that are translated into protein. These protein-coding regions contain most of the currently-known disease-causing genetic mutations. The American College of Medical Genetics and Genomics (ACMG) has recommended the reporting to patients of clinically actionable incidental genetic findings in the course of clinical exome testing. Specifically, mutations ...

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

2014-05-31
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013. The drug also has shown dramatic responses in ...

Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells

2014-05-31
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, ...

ASCO: One step closer to a breath test for lung cancer

2014-05-31
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. "This could totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer," ...

ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer

2014-05-31
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid ...

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy
2014-05-31
CHICAGO — In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's 2014 Annual Meeting in Chicago, examines a specific mutation in the BRAF gene, which is present in 5 to 10 percent of colorectal cancer patients. Previous research identified this mutation ...

Immune therapy for advanced bladder cancer yields promising results

2014-05-31
New Haven, Conn. — A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago. The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 ...

Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL

2014-05-31
COLUMBUS, Ohio – In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. Ibrutinib (Imbruvica) is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL, the most common form of leukemia, causes a gradual increase ...

LAST 30 PRESS RELEASES:

Young minds, big ideas: Florida’s first Invention Convention ignites innovation at USF

New study reveals how to make prescribed forest fires burn safer and cleaner

Inactive components in agricultural runoff may be hidden contributors to drinking water hazards

Colombia’s peatlands could be a crucial tool to fight climate change. But first we have to find them

Researchers refine a hybrid music therapy intervention for patients with cardiac and pulmonary conditions

Research Spotlight: Combining dexmedetomidine with spinal anesthesia prolongs pain relief and decreases shivering during surgery

Pennington Biomedical’s 2025 Bray Obesity Symposium to offer on-demand continuing education for physicians

Unlocking faster orthodontic treatments: the role of atf6 in bone remodeling

SwRI-led Lucy mission survey of main belt asteroid Donaldjohanson imminent

New bat cell lines and reagents help to study bat antiviral immune responses against hantaviruses and coronaviruses

Preterm birth might be predicted with high accuracy with new cheap, non-invasive test, based on cell-free DNA collected in standard early pregnancy testing

CVD researcher/clinician named editor-in-chief of Circulation: Genomic and Precision Medicine.

Holy shift: More Americans finding faith outside church

New analysis underscores health risks of e-cigarettes

USTC develops high-performance biomimetic proton gating system

Uncovering the molecular drivers of liver cancer

A bowling revolution: Modeling the perfect conditions for a strike

Simulate sound in 3D at a finer scale than humans can perceive

Screening history, stage at diagnosis, and mortality in screen-detected breast cancer

Pitt researchers release Phage images with unprecedented detail

Sound wave research for breast cancer receives $5.5 million

Gene variant linked to benign prostate hyperplasia risk in Lebanese men

Teoxane announces new study reinforcing the biocompatibility, safety and efficacy of RHA®4 in dynamic facial support

Study identifies U.S. hotspots for drinking water quality violations and lack of access to safe, clean water

Busted! Researchers revolutionize fraud detection with machine learning

Earthworm-inspired multimodal pneumatic continuous soft robot enhanced by winding transmission

Coastal heritage threatened by climate change

A tale of two hummingbird bills


Corn leads to improved performance in lithium-sulfur batteries

SynGAP Research Fund (SRF), dba Cure SYNGAP1, announces Board of Trustees Update 2025

[Press-News.org] The ethics of knowing where to stop treatment in a sick and elderly patient